Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
Related Questions
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
How do you monitor and manage minimal residual disease (MRD) in patients with core-binding factor (CBF) AML who are in remission post-induction and consolidation therapy?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
In patients with Philadelphia-negative ALL who are transplant ineligible, is there any data to guide the duration of maintenance POMP therapy?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
